(Q35873788)

10 August 2017

1 reference

title

Tuberculosis vaccine development: research, regulatory and clinical strategies (English)

1 reference

10 August 2017

1 reference

Michael J Brennan

1

1 reference

10 August 2017

Sheldon L Morris

series ordinal

2

1 reference

10 August 2017

Christine F Sizemore

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

1493-1504

1 reference

Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Immune responses to intracellular bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Immune evasion by Mycobacterium tuberculosis: living with the enemy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Comparative and functional genomics of the Mycobacterium tuberculosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

The PE multigene family: a 'molecular mantra' for mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Expression, characterization and subcellular localization of the Mycobacterium tuberculosis PPE gene Rv1917c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Use of fluorescence induction and sucrose counterselection to identify Mycobacterium tuberculosis genes expressed within host cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Tuberculosis vaccine development: recent progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Comparative genomics of BCG vaccines by whole-genome DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

ESAT-6 subunit vaccination against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Vaccination against tuberculosis by DNA injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Protection to mice afforded by BCG vaccines against an aerogenic challenge by three mycobacteria of decreasing virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Therapy of tuberculosis in mice by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Boosting vaccine for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Propelling novel vaccines directed against tuberculosis through the regulatory process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

The Koch phenomenon and delayed hypersensitivity: 1891-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

BCG: the challenge continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Modern vaccines. Mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Engaging the community in research: lessons learned from the malaria vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

South African village prepares for first HIV vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Ethics of clinical research in the developing world.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

The Potential of the ESAT-6 Antigen Secreted by Virulent Mycobacteria for Specific Diagnosis of Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1493

10.1517/14712598.4.9.1493

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference